他氟前列素上市后的预算影响分析

Budget impact analysis of tafluprost after its introduction into market

目的:通过对他氟前列素进行上市后的预算影响分析,为药品报销目录的遴选、医保支付价格的决策及医疗机构用药方案的制定提供科学依据,以促进卫生资源的合理配置。方法:构建预算影响分析模型,测算他氟前列素在中国上市并进入医保目录对医保支出的预期影响。结果:如果2015年前列腺素类新药他氟前列素在中国上市并进入医保目录,由于其相对较低的日治疗费用,预计将会节约医保预算,估计到2019年将能节约的医保预算总费用为7 710万元。结论:他氟前列素上市并进入医保目录后将能够有效降低医保总支出,并且随着他氟前列素市场份额的增大,所能节约的医保费用将越来越大。

Objective： To conduct a budget impact analysis of tafluprost after its introduction into the market to provide scientific evidence for decision making process related to reimbursement formulary,reimbursement price,along with therapeutic regimen,and promote rational allocation of health resources. Methods： Budget impact analysis model was constructed to measure the expected changes in the expenditure of health care system after the adoption of tafluprost in China. Results： Due to its relatively low daily cost,tafluprost would save the budget after the adoption of tafluprost in China in the year of 2015. The total budget savings was expected to be 77. 10 million yuan in 2019. Conclusion： The adoption of tafluprost in China will save healthcare budget effectively and with the market share of tafluprost increasing,it will save more.